Picture of Rani Therapeutics Holdings logo

RANI Rani Therapeutics Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-26.27%
3m-18.1%
6m-53.03%
1yr-84.71%
Volume Change (%)
10d/3m-73.15%
Price vs... (%)
52w High-86.29%
50d MA-19.19%
200d MA-44.98%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-318.43%
Return on Equity-404.07%
Operating Margin-5186.19%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Rani Therapeutics Holdings EPS forecast chart

Profile Summary

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    December 31st, 2024
    Incorporated
    April 6th, 2021
    Public Since
    July 30th, 2021
    No. of Shareholders
    138
    No. of Employees
    105
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    57,542,105

    RANI Share Price Performance

    Upcoming Events for RANI

    Rani Therapeutics Holdings Inc Annual Shareholders Meeting

    Rani Therapeutics Holdings Inc Annual Shareholders Meeting

    Similar to RANI

    Picture of 89bio logo

    89bio

    us flag iconNASDAQ Global Market

    Picture of Abivax SA logo

    Abivax SA

    us flag iconNASDAQ Global Market

    Picture of ABPRO Holdings logo

    ABPRO Holdings

    us flag iconNASDAQ Global Market

    Picture of AC Immune SA logo

    AC Immune SA

    us flag iconNASDAQ Global Market

    Picture of Acrivon Therapeutics logo

    Acrivon Therapeutics

    us flag iconNASDAQ Global Market

    FAQ

    0